Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301
Takenaka, T.; Itoh, K.; Suzuki, T.; Utsunomiya, A.; Matsuda, S.; Chou, T.; Sai, T.; Sano, M.; Konda, S.; Ohno, T.; Mikuni, C.; Deura, K.; Yamada, T.; Mizorogi, F.; Nagoshi, H.; Tomonaga, M.; Hotta, T.; Kawano, K.; Tsushita, K.; Hirano, M.; Shimoyama, M.
International Journal of Hematology 79(2): 165-173
2004
ISSN/ISBN: 0925-5710
PMID: 15005346
DOI: 10.1532/ijh97.03115
Accession: 012410539
To investigate whether combination chemotherapy with vincristine, cyclophosphamide, prednisolone, and melphalan (COP/MP) with the addition of ranimustine (MCNU) (MCNU-COP/MP) is superior to the slightly modified COP/MP (mCOP/MP) regimen in multiple myeloma (MM), a multicenter randomized study was performed.
PDF emailed within 0-6 h: $19.90
Related References
Chou, T.; Tobinai, K.; Uike, N.; Asakawa, T.; Saito, I.; Fukuda, H.; Mizoroki, F.; Ando, K.; Iida, S.; Ueda, R.; Tsukasaki, K.; Hotta, T.; Aikawa, K.; Matsuda, S.; Nakata, M.; Oshimi, K.; Ohmachi, K.; Ohnishi, K.; Kinoshita, T.; Okamura, S.; Tsukada, J. 2011: Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112 Japanese Journal of Clinical Oncology 41(4): 586-589Imamura, Y.; Takagi, T.; Yawata, Y.; Nishinarita, S.; Kosaka, M.; Mikuni, C.; Takatsuki, K.; Sezaki, T.; Mori, M.; Tsuchiya, J. 1994: Combination chemotherapy with MCNU, vindesine, melphalan, and prednisolone (MCNU-VMP therapy) in induction therapy for multiple myeloma. Japan Myeloma Study Group International Journal of Hematology 59(2): 113-123
Takenaka, T.; Shirakawa, S.; Mikuni, C.; Sai, T.; Shimamoto, Y.; Araki, K.; Hirano, M.; Miura, A.; Ohno, Y.; Ichimaru, M.; Hanada, S.; Inaba, S.; Konishi, H.; Toki, H.; Tajima, K.; Niimi, M.; Fukuda, H.; Shimoyama, M. 1999: Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase Ii study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group Japanese Journal of Clinical Oncology 29(10): 485-489
Shimizu, K.; Kamiya, O.; Hamajima, N.; Mizuno, H.; Kobayashi, M.; Hirabayashi, N.; Takeyama, H.; Kato, R.; Kawashima, K.; Nitta, M. 1990: Multi-drug combination therapy with vincristine-melphalan-cyclophosphamide-prednisolone was more effective than cyclophosphamide-prednisolone in stage IIi myeloma. the Nagoya Myeloma Cooperative Study Group Japanese Journal of Cancer Research: Gann 81(12): 1320-1327
Peest, D.; Schmoll, H.J.; Schedel, I.; Deicher, H.; Boll, I.; Essers, U.; Gamm, H.; Glueck, S.; Goerg, K.; E.A. 1986: Melphalan and prednisolone vs. vincristine cyclophosphamide melphalan and prednisolone a prospective randomized trial in stage ii and iii multiple myeloma Journal of Cancer Research and Clinical Oncology 111(Suppl): S8
Glueck, S.; Schoppe, W.D.; Schneider, W. 1986: Vincristine cyclophosphamide melphalan prednisolone chemotherapy of multiple myeloma after ineffective melphalan prednisolone therapy Blut 53(3): 227
Kyle, R.A.; Jacobus, S.; Friedenberg, W.R.; Slabber, C.F.; Rajkumar, S.V.; Greipp, P.R. 2009: The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and alpha(2)beta interferon versus VBMCP: results of a phase IIi Eastern Cooperative Oncology Group Study E5A93 Cancer 115(10): 2155-2164
Keldsen, N.; Bjerrum, O.W.; Dahl, I.M.; Drivsholm, A.; Ellegaard, J.; Gadeberg, O.; Gimsing, P.; Grønvold, T.; Hansen, M.M.; Hippe, E. 1993: Multiple myeloma treated with mitoxantrone in combination with vincristine and prednisolone (NOP regimen) versus melphalan and prednisolone: a phase IIi study. Nordic Myeloma Study Group (NMSG) European Journal of Haematology 51(2): 80-85
Takenaka, T.; Mikuni, C.; Miura, A.; Sasaki, T.; Suzuki, H.; Hotta, T.; Hirano, M.; Fukuhara, S.; Sugiyama, H.; Nasu, K.; Dohi, H.; Kozuru, M.; Tomonaga, M.; Tajima, K.; Niimi, M.; Fukuda, H.; Mukai, K.; Shimoyama, M. 2000: Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase Ii study (JCOG 8905). the Lymphoma Study Group of the Japan Clinical Oncology Group Japanese Journal of Clinical Oncology 30(3): 146-152
Oken, M.M.; Harrington, D.P.; Abramson, N.; Kyle, R.A.; Knospe, W.; Glick, J.H. 1997: Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: Results of Eastern Cooperative Oncology Group Study E2479 Cancer 79(8): 1561-1567
Kabir, A.L.; Rahman, M.J.; Begum, M.; Dipta, T.F.; Baqui, M.N.; Aziz, A.; Rahman, F.; Debnath, R.C.; Habib, M.A. 2012: Response of vincristine, melphalan, cyclophosphamide and prednisolone in refractory multiple myeloma Mymensingh Medical Journal: Mmj 21(1): 114-119
Takagi, T.; Oguro, M.; Sakai, C. 1986: Combination chemotherapy with melphalan, cyclophosphamide, vincristine, ACNU and prednisolone (MEV(Ac)P) for multiple myeloma Japanese Journal of Clinical Hematology 27(12): 2249-2253
Shimizu K.; Kamiya O.; Hamajima N.; Mizuno H.; Kobayashi M.; Hirabayashi N.; Takeyama H.; Kato R.; Kawashima K.; Et Al 1990: Multi drug combination therapy with vincristine melphalan cyclophosphamide prednisolone was more effective than cyclophosphamide prednisolone in stage iii myeloma Japanese Journal of Cancer Research 81(12): 1320-1326
Kazuyuki Shimizu; Osamu Kamiya; Nobuyuki Hamajima; Harumitsu Mizuno; Masahide Kobayashi; Noriyuki Hirabayashi; Hideo Takeyama; Ryoichi Kato; Kohei Kawashima; Masakazu Nitta; Tomomitsu Hotta; Makoto Utsumi; Eiichi Nagura 1990: Multi-drug Combination Therapy with Vincristine-Melphalan-Cyclophosphamide-Prednisolone Was More Effective than Cyclophosphamide-Prednisolone in Stage III Myeloma Cancer Science 81(12): 1320-1327
Poenisch, W.; Storch, H. 1987: Results of a cytostatic chemotherapy in outdoor patients with myeloma disease using a modified vincristine melphalan cyclophosphamide and prednisolone scheme Wissenschaftliche Zeitschrift der Karl-Marx-Universitaet Leipzig Mathematisch-Naturwissenschaftliche Reihe 36(5): 508-512
Kagami, Y.; Itoh, K.; Tobinai, K.; Fukuda, H.; Mukai, K.; Chou, T.; Mikuni, C.; Kinoshita, T.; Fukushima, N.; Kiyama, Y.; Suzuki, T.; Sasaki, T.; Watanabe, Y.; Tsukasaki, K.; Hotta, T.; Shimoyama, M.; Ogura, M.; Mikuni, C.; Kasai, M.; Miura, A.; Sai, T.; Matsuda, S.; Ohtsu, T.; Tobinai, K.; Kawano, K.; Sasaki, T.; Yamada, S.; Mizoroki, F.; Hotta, T.; Nagoshi, H.; Chou, T.; Shimizu, S.; Ueda, T.; Ogura, M.; Shimoyama, M.; Kinoshita, T.; Minami, S.; Ueda, R.; Suzuki, T.; Ohno, T.; Abe, M.; Fukuhara, S.; Ohno, Y.; Sezaki, T.; Okabe, K.; Sakai, Y.; Izumi, Y.; Shimamoto, Y.; Tomonaga, M.; Ikeda, S.; Takatsuki, K.; Kawano, H.; Utsunomiya, A.; Tara, M.; Araki, K. 2012: Phase Ii study of cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy for newly diagnosed patients with low- and low-intermediate risk, aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG9508 International Journal of Hematology 96(1): 74-83
Kato, K; Muro, K; Ando, N; Nishimaki, T; Ohtsu, A; Aogi, K; Aoyama, N; Nagai, K; Kato, H 2014: A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI) Esophagus 11(3): 183-188
Uzuka, Y.; Saito, Y.; Takahashi, H.; Komatsu, M.; Ito, T. 1989: Combination chemotherapy of multiple myeloma--BCNU.cyclophosphamide.procarbazine.prednisolone and MCNU.cyclophosphamide.procarbazine.prednisolone therapy Gan to Kagaku Ryoho. Cancer and ChemoTherapy 16(6): 2269-2273
Giles, F.J.; Wickham, N.R.; Rapoport, B.L.; Somlo, G.; Lim, S.W.; Shan, J.; Lynott, A.M. 2000: Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: An international oncology study group (IOSG) phase II protocol American Journal of Hematology 63(3): 125-130
Wada, M.; Mizoguchi, H.; Kuriya, S.I.; Taguchi, H.; Kawamura, T.; Maekawa, I.; Shimazaki, C.; Sato, Y.; Niho, Y.; Miyazaki, T.; Shibata, A.; Kitani, T.; Hamajima, N.; Ohno, R. 2000: Induction therapy consisting of alternating cycles of ranimustine, vincristine, melphalan, dexamethasone and interferon alpha (ROAD-IN) and a randomized comparison of interferon alpha maintenance in multiple myeloma: a co-operative study in Japan British Journal of Haematology 109(4): 805-814